Xiamen Yan Palace Bird’s Nest Industry Co., Ltd. Announces Robust 2025 Annual Results: Gross Margin Expansion, Strong Profit Growth, and Strategic Developments

Key Financial Highlights for Investors

• Revenue: RMB2,000.6 million, a slight decrease of 2.41% from RMB2,050.0 million in 2024, mainly due to a structural consumption adjustment and weaker demand for high-end consumer goods.
• Gross Profit: Rose 5.74% to RMB1,070.9 million from RMB1,012.8 million, with gross profit margin improving to 53.53% (from 49.40%).
• Net Profit: Surged 19.3% year-on-year to RMB191.4 million, up from RMB160.4 million.
• Earnings Per Share (Basic and Diluted): Both at RMB0.41 (2024: RMB0.34).
• Dividend: Proposed final dividend of RMB2.66 per ten shares, subject to AGM approval.
• Cash Position: Cash and cash equivalents increased 51.27% to RMB636.1 million.
• Net Current Assets: Up to RMB492.4 million (2024: RMB402.0 million).
• Return on Equity: 23.9% (2024: 20.5%).
• Gearing Ratio: Improved to 13.4% from 17.0%.

Key Developments and Strategic Initiatives

1. Brand Leadership and Market Position

• Yan Palace was named to the “List of Chinese Renowned Consumer Brands 2025” and ranked first in the China Brand Power IndexSM (C-BPI) for the sixth consecutive year, reflecting strong brand equity and influence in the edible bird’s nest (EBN) market.
• High-profile brand ambassadors: Zhu Yilong joined Gong Li in a dual-ambassador strategy, boosting brand recognition among high-end and younger demographics.
• Multiple IP collaborations (e.g., Zootopia, Beijing Folk Art Intangible Cultural Heritage Research Institute) resulted in new co-branded products, expanding reach and relevance.
• International expansion efforts, notably in Singapore, included local celebrity endorsement and outdoor advertising campaigns. Trademark portfolio expanded to 528 registrations worldwide, with successful defense of brand rights in court cases.

2. Channel Optimization and New Growth Curves

• Revenue from offline channels was RMB730.0 million (36.49% of total), with continued network expansion: 112 self-operated stores and 620 distributor-operated stores by year-end.
• Online channels contributed RMB1,270.6 million (63.51% of total), up 2.29% year-on-year, reflecting robust e-commerce execution, especially on Douyin, Xiaohongshu, and via influencer collaborations.
• Innovative new retail strategy integrated online/offline channels, leveraging instant delivery platforms (e.g., JD NOW, Meituan) to enhance consumer experience and create a new growth driver.
• Private domain channels (Golden Yan Club) surpassed 580,000 members, with total online registered members reaching 8.95 million. Activities such as golf tournaments and exclusive salons drove member engagement and sales.
• New overseas stores opened in New York and Singapore, with localized operational models. KA channels (key accounts) expanded to major supermarket chains, with strong performance during the 2026 Spring Festival (over 70% sell-through at Yonghui Supermarket).

3. Smart Manufacturing and Cost Optimization

• The Yan Palace EBN smart factory—awarded “Fujian Province Benchmark Enterprise in Digitalization”—completed digital transformation, deploying MES, WMS, and WES software, and using AI/SCADA for process optimization and quality control.
• Cost of sales decreased 10.36% to RMB929.7 million, reflecting improved production efficiency and cost structure optimization. This contributed to the significant expansion in gross profit margin.
• Capital expenditure was sharply reduced to RMB28.2 million (from RMB114.2 million), indicating completion of major investments and a shift to cost efficiency.

4. Research & Development and Product Innovation

• R&D expenses decreased to RMB25.5 million as experimental design was optimized, but research output remained strong: 223 valid patents, 67 academic papers published, and leadership in national and international EBN standards development.
• Major product advances included:
  • The launch of “Yan Palace – Supercritical Hot EBN” leveraging patented technology for rapid preparation.
  • Groundbreaking research on EBN peptide, including a world-first patent for its preparation, human clinical validation, and new product launches (oral peptide, probiotic powder, walnut milk, etc.).
• Standard setting: Led or participated in one national, four industry, and 28 group standards, reinforcing industry leadership and credibility.

5. Financial & Capital Management

• Robust liquidity with cash and equivalents at RMB636.1 million, no outstanding loans, and banking facilities of RMB142 million (unused).
• Lease liabilities form the bulk of indebtedness (RMB111.6 million), no asset pledges or material contingent liabilities.
• The company repurchased 3,656,800 H shares in 2025 for HK\$28.43 million, a move aimed at enhancing shareholder value and potentially supporting share price.
• All proceeds from the 2023 IPO have been fully utilized as planned, with no unutilized proceeds remaining at year-end 2025.

6. Corporate Governance and Shareholder Matters

• The Board proposes a final dividend of RMB2.66 per ten shares, subject to approval at the AGM scheduled for May 11, 2026. The ex-dividend date is May 21, 2026, with payment expected on June 5, 2026.
• The company maintained compliance with all corporate governance and regulatory requirements, including public float and director trading codes.
• Employee base stood at 1,635, with total labor costs of RMB292.28 million. The H Share Incentive Scheme continues to incentivize core talent.

Strategic Outlook for 2026

• The company will focus on four pillars: brand enhancement, product innovation, channel expansion, and smart manufacturing.
• Plans to launch differentiated EBN products for online/offline new retail, further expand KA (key account) channels, upgrade its “Yan Yu New Tea” youth-focused product line, and continue leveraging EBN peptide innovation for new biotech applications.
• AI-driven R&D will be deployed to accelerate product development and optimize formulas.
• Management views 2026 as a critical year for high-quality growth, aiming to deepen its leadership in the EBN sector and capture new health consumption trends.

Potentially Price-Sensitive/Shareholder-Impacting Information

• Gross profit margin expansion and profit surge, despite revenue dip, signal strong operational leverage and cost control—likely to support share value.
• Proposed final dividend increase (RMB2.66 per ten shares vs. RMB2.15 prior year) may positively impact investor sentiment.
• Large-scale share buyback (3.65 million H shares) and robust cash position indicate management confidence and potential support for the share price.
• Significant advances in smart factory automation and EBN peptide innovation position the company as a technology and product leader, potentially driving future growth and market share gains.
• All IPO proceeds fully deployed as planned, with no unutilized capital, signaling effective use of shareholder funds.

Important Dates for Shareholders

• AGM: May 11, 2026 (register by May 5, 2026 to vote)
• Final Dividend Record Date: May 21, 2026 (register by May 15, 2026 to qualify)
• Dividend Payment Expected: June 5, 2026 (subject to approval)

Conclusion

Xiamen Yan Palace Bird’s Nest Industry Co., Ltd. delivered a resilient performance in 2025, with improved profitability, strong cash flows, enhanced shareholder returns, and significant progress in brand, technology, and channel initiatives. The company’s strategic focus on innovation, digital transformation, and multi-channel expansion—coupled with prudent financial management and shareholder-friendly actions—positions it well for sustainable growth. These developments, especially the margin expansion, rising dividends, and share buybacks, are likely to be of high interest to investors and may influence the company’s share price.

Disclaimer: This article is a summary and interpretation of the official financial results announcement of Xiamen Yan Palace Bird’s Nest Industry Co., Ltd. for the year ended December 31, 2025. It is intended for informational purposes only and does not constitute investment advice or a solicitation to buy or sell securities. Investors should refer to official sources and consult professional advisors before making investment decisions. The author assumes no responsibility for actions taken based on the information provided above.

View YAN PALACE Historical chart here